Floatz logo

Tesamorelin

Mild Cognitive Impairment

University of California, San Diegoprotein_peptidePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
73/ 100

Competitive context

150 Active assets in the Mild Cognitive Impairment cohort.

Asset / SponsorPhaseRating
Ginkgo Biloba Extract
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase 4BBB
Nicotine
University of Southern California
Phase 2BBB
Rivastigmine
Singapore General Hospital
Phase 4BBB
Oxybutynin
University of Alberta
Phase 4BBB
Metformin
Fudan University
Phase 4BB

View all 50 →

Same molecule, other indications

Tesamorelin is also rated in:

lipodystrophyDormant
B
Indicative ·
62 / 100
View asset →
Body CompositionDormant
B
Indicative ·
60 / 100
View asset →
isolated congenital growth hormone deficiencyDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →